Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03050151 · ClinicalTrials.gov registry record · Phase 1
Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 176
- Enrollment target
NCT03050151 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 176 participants.
The verdict
NCT03050151, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 176 participants
- Enrollment target
Study Summary
To collect data on actual-use to assess technical performance and user injections of dupilumab auto-injection device by patients with atopic dermatitis (AD).
Interventions
- DRUG Dupilumab
- DEVICE Auto-injector Device
- DEVICE Prefilled syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2017-02-28 |
| Est. Completion | 2018-02-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03050151
The ClinicalTrials.gov registry entry for NCT03050151 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dupilumab is the first listed.
NCT03050151 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03050151 about?
NCT03050151 is a clinical study titled "Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis". To collect data on actual-use to assess technical performance and user injections of dupilumab auto-injection device by patients with atopic dermatitis (AD).
What is the current status of trial NCT03050151?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 176 participants. The study started on 2017-02-28. Estimated completion is 2018-02-12.
What interventions are being tested in trial NCT03050151?
The interventions under investigation include: Dupilumab (DRUG), Auto-injector Device (DEVICE), Prefilled syringe (DEVICE).
Who is sponsoring clinical trial NCT03050151?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.